Axsome Therapeutics Inc (OQ:AXSM)

Jun 26, 2020 09:31 am ET
Thinking about trading options or stock in Axsome Therapeutics, Virgin Galactic, Dynavax Technologies, Big Lots, or Walt Disney?
NEW YORK, June 26, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for AXSM, SPCE, DVAX, BIG, and DIS....
Jun 26, 2020 07:00 am ET
Axsome Therapeutics Receives FDA Breakthrough Therapy Designation for AXS-05 for the Treatment of Alzheimer’s Disease Agitation
Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough...
Jun 04, 2020 07:00 am ET
Axsome Therapeutics to Present at Upcoming Investor Conferences
Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, will participate in two upcoming investor conferences: William Blair 40th Annual Growth...
May 29, 2020 07:00 am ET
Axsome Therapeutics Presents Data from GEMINI Phase 3 Trial of AXS-05 in Major Depressive Disorder at the 2020 American Society for Clinical Psychopharmacology Annual Meeting
Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, today announced that data from the GEMINI Phase 3 trial of AXS-05 in major depressive...
May 26, 2020 07:00 am ET
Axsome Therapeutics to Host 2020 Annual Meeting of Stockholders Virtually
Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, today announced the Company’s 2020 Annual Meeting of Stockholders will now be held in a...
May 08, 2020 07:00 am ET
Axsome Therapeutics Reports First Quarter 2020 Financial Results and Provides Business Update
Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, today reported financial results for the first quarter ended March 31, 2020. “The recent...
Apr 30, 2020 07:00 am ET
Axsome Therapeutics to Report First Quarter 2020 Financial Results on May 8, 2020
Axsome Therapeutics, Inc. (NASDAQ: AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, today announced that it will report its financial results for the first...
Apr 27, 2020 09:31 am ET
Thinking about trading stocks or options in Apple, Axsome Therapeutics, Walt Disney, Royal Caribbean Cruises, or Trade Desk?
NEW YORK, April 27, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for AAPL, AXSM, DIS, RCL, and TTD....
Apr 27, 2020 06:00 am ET
Axsome Therapeutics Announces AXS-05 Achieves Primary Endpoint in the ADVANCE-1 Pivotal Phase 2/3 Trial in Alzheimer’s Disease Agitation
Axsome Therapeutics, Inc. (NASDAQ: AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, today announced that AXS-05, a novel, oral, investigational NMDA receptor...
Apr 06, 2020 06:00 am ET
Axsome Therapeutics Announces AXS-07 Achieves Both Co-Primary Endpoints and Prevents Migraine Pain Progression in the INTERCEPT Phase 3 Trial in the Early Treatment of Migraine
Axsome Therapeutics, Inc. (NASDAQ: AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, today announced that AXS-07 substantially and significantly eliminated...
Mar 30, 2020 06:00 am ET
Axsome Therapeutics Announces Topline Results of the STRIDE-1 Phase 3 Trial in Treatment Resistant Depression and Expert Call to Discuss Clinical Implications
Axsome Therapeutics, Inc. (NASDAQ: AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, today announced that AXS-05, a novel, oral, investigational NMDA receptor...
Mar 20, 2020 07:00 am ET
Axsome Therapeutics Accelerates Completion of the ADVANCE-1 Phase 2/3 Trial of AXS-05 in Alzheimer’s Disease Agitation
Axsome Therapeutics, Inc. (NASDAQ: AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, today announced that it is accelerating the completion of the ADVANCE-1...
Mar 12, 2020 07:00 am ET
Axsome Therapeutics Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Business Update
Axsome Therapeutics, Inc. (NASDAQ: AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, today reported financial results for the fourth quarter and year ended...
Mar 05, 2020 07:00 am ET
Axsome Therapeutics Announces the Promotion of Mark Jacobson to Chief Operating Officer
Axsome Therapeutics, Inc. (NASDAQ: AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, today announced the appointment of Mark Jacobson as Chief Operating...
Mar 04, 2020 07:00 am ET
Axsome Therapeutics to Report Fourth Quarter and Full Year 2019 Financial Results on March 12, 2020
Axsome Therapeutics, Inc. (NASDAQ: AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, today announced that it will report its financial results for fiscal year...
Feb 20, 2020 07:00 am ET
Axsome Therapeutics Completes Patient Enrollment in the INTERCEPT Phase 3 Trial of AXS-07 in the Early Treatment of Migraine
Axsome Therapeutics, Inc. (NASDAQ: AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, today announced the completion of patient enrollment in the INTERCEPT...
Feb 19, 2020 07:00 am ET
Axsome Therapeutics to Present at Upcoming Investor Conferences
Axsome Therapeutics, Inc. (NASDAQ: AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, today announced that Herriot Tabuteau, MD, Axsome’s Chief Executive...
Jan 22, 2020 07:00 am ET
Axsome Therapeutics Completes Patient Randomization in the STRIDE-1 Phase 3 Trial of AXS-05 in Treatment Resistant Depression
Axsome Therapeutics, Inc. (NASDAQ: AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, today announced the completion of patient randomization in the STRIDE-1...
Jan 13, 2020 06:00 am ET
Axsome Therapeutics Enters into Exclusive License Agreement with Pfizer Inc. for Pfizer’s Reboxetine Clinical and Nonclinical Data and for New Phase 3 Esreboxetine Product Candidate
Axsome Therapeutics, Inc. (NASDAQ: AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, has entered into an agreement with Pfizer Inc. (NYSE: PFE) for an...
Dec 30, 2019 06:15 am ET
Axsome Therapeutics Announces AXS-07 Achieves Co-Primary and Key Secondary Endpoints in MOMENTUM Phase 3 Migraine Trial in Patients with History of Inadequate Response
Axsome Therapeutics, Inc. (NASDAQ: AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, today announced that AXS-07, Axsome’s novel, oral, multi-mechanistic...
Dec 23, 2019 04:19 pm ET
Axsome Therapeutics Announces Closing of $200 Million Public Offering of Common Stock, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
Axsome Therapeutics, Inc. (NASDAQ: AXSM) (“Axsome” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, today announced the closing of its previously...
Dec 19, 2019 07:05 am ET
Axsome Therapeutics Announces Pricing of Public Offering of $174 Million of Shares of Common Stock
Axsome Therapeutics, Inc. (Nasdaq: AXSM) (“Axsome” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, today announced the pricing of an underwritten...
Dec 18, 2019 04:01 pm ET
Axsome Therapeutics Announces Proposed Public Offering of Common Stock
Axsome Therapeutics, Inc. (Nasdaq: AXSM) (“Axsome” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, today announced that it intends to offer and...
Dec 17, 2019 07:00 am ET
Axsome Therapeutics Added to NASDAQ Biotechnology Index
Axsome Therapeutics, Inc. (NASDAQ: AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, has been selected for addition to the NASDAQ Biotechnology Index®...
Dec 16, 2019 06:00 am ET
Axsome Therapeutics Announces AXS-05 Achieves Primary Endpoint in GEMINI Phase 3 Trial in Major Depressive Disorder
Axsome Therapeutics, Inc. (NASDAQ: AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, today announced that AXS-05, a novel, oral, investigational NMDA receptor...
Dec 03, 2019 06:00 am ET
Axsome Therapeutics Announces AXS-12 Achieves Primary Endpoint in CONCERT Phase 2 Trial in Narcolepsy
Axsome Therapeutics, Inc. (NASDAQ: AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, today announced that AXS-12 (reboxetine) met the prespecified primary...
Nov 21, 2019 07:00 am ET
Axsome Therapeutics to Host Investor R&D Call with Key Opinion Leaders Focusing on AXS-07 and the Unmet Needs in the Acute Treatment of Migraine
Axsome Therapeutics, Inc. (NASDAQ: AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, is hosting an R&D conference call and webcast with slides on Monday,...
Nov 07, 2019 07:00 am ET
Axsome Therapeutics Reports Third Quarter 2019 Financial Results and Provides Business Update
Axsome Therapeutics, Inc. (NASDAQ: AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, today reported financial results for the third quarter ended September 30,...
Oct 29, 2019 07:00 am ET
Axsome Therapeutics to Report Third Quarter 2019 Financial Results on November 7, 2019
Axsome Therapeutics, Inc. (NASDAQ: AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, today announced that it will report its financial results for the third...
Oct 28, 2019 07:05 am ET
Axsome Therapeutics Announces Results of MINDSET Physician Survey Affirming Unmet Need and Favorable Profile of AXS-07 in the Acute Treatment of Migraine
Axsome Therapeutics, Inc. (NASDAQ: AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, today announced results of the “Migraine Treatment Needs and Physician...
Oct 28, 2019 07:00 am ET
Axsome Therapeutics Announces Continued Progress in Clinical Development of AXS-07 for the Acute Treatment of Migraine
Axsome Therapeutics, Inc. (NASDAQ: AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, announces the initiation of the INTERCEPT trial, a Phase 3 study...
Oct 21, 2019 07:00 am ET
Axsome Therapeutics Completes Patient Enrollment in the CONCERT Phase 2 Trial of AXS-12 in Narcolepsy
Axsome Therapeutics, Inc. (NASDAQ: AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, today announced the completion of patient enrollment in the CONCERT study,...
Oct 16, 2019 07:00 am ET
Axsome Therapeutics Announces Completion of Patient Enrollment in the GEMINI Phase 3 Trial of AXS-05 in Major Depressive Disorder
Axsome Therapeutics, Inc. (NASDAQ: AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, today announced the completion of patient enrollment in the GEMINI study,...
Oct 02, 2019 07:00 am ET
Axsome Therapeutics to Provide Update on Continued Progress at the 2019 Cantor Global Healthcare Conference
Axsome Therapeutics, Inc. (NASDAQ: AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, will participate in the 2019 Cantor Global Healthcare Conference on...
Sep 05, 2019 07:00 am ET
Axsome Therapeutics Presents Positive AXS-07 Phase 1 Trial Results at the 19th Congress of the International Headache Society
Axsome Therapeutics, Inc. (NASDAQ: AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, will present positive results from a Phase 1 pharmacokinetic trial of...
Sep 03, 2019 07:00 am ET
Axsome Therapeutics to Present at the Morgan Stanley 17th Annual Global Healthcare Conference
Axsome Therapeutics, Inc. (NASDAQ: AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, will participate in the Morgan Stanley 17th Annual Global Healthcare...
Aug 20, 2019 07:00 am ET
Axsome Therapeutics Appoints David Marek as Chief Commercial Officer
Axsome Therapeutics, Inc. (NASDAQ: AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, today announced the appointment of David Marek as Chief Commercial...
Aug 08, 2019 07:00 am ET
Axsome Therapeutics Reports Second Quarter 2019 Financial Results and Provides Business Update
Axsome Therapeutics, Inc. (NASDAQ: AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, today reported financial results for the second quarter ended June 30,...
Jul 30, 2019 07:00 am ET
Axsome Therapeutics To Report Second Quarter 2019 Financial Results On August 8, 2019
Axsome Therapeutics, Inc. (NASDAQ: AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, today announced that it will report its financial results for the second...
Jul 29, 2019 07:00 am ET
Axsome Therapeutics Amends Silicon Valley Bank Loan Agreement Increasing Financial Flexibility
Axsome Therapeutics, Inc. (NASDAQ: AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, announced that it has amended its existing $24 million term loan facility...
Jul 01, 2019 07:00 am ET
Axsome Therapeutics Added to Russell 3000® and Russell 2000® Indexes
Axsome Therapeutics, Inc. (NASDAQ: AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, has been added to the Russell 3000® and Russell 2000® Indexes, as part of...
Jun 24, 2019 07:00 am ET
Axsome Therapeutics Initiates GEMINI Phase 3 Trial of AXS-05 in Major Depressive Disorder
Axsome Therapeutics, Inc. (NASDAQ: AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, enrolled the first patient in its GEMINI (Glutamatergic and Monoaminergic...
Jun 07, 2019 07:00 am ET
Axsome Therapeutics Provides Update on Continued Progress at Annual Stockholders’ Meeting
Axsome Therapeutics, Inc. (NASDAQ: AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, is providing the following update on the Company’s continued progress at...
May 21, 2019 07:00 am ET
Axsome Therapeutics To Present Data From ASCEND Phase 2 Trial Of AXS-05 In Major Depressive Disorder At The 2019 American Society For Clinical Psychopharmacology Annual Meeting
Axsome Therapeutics, Inc. (NASDAQ: AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, today announced that data from the Phase 2 ASCEND trial of AXS-05 in major...
May 09, 2019 07:00 am ET
Axsome Therapeutics Reports First Quarter 2019 Financial Results and Provides Business Update
Axsome Therapeutics, Inc. (NASDAQ: AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, today reported financial results for the first quarter ended March 31,...
May 06, 2019 07:00 am ET
Axsome Therapeutics Announces Acceleration of MOMENTUM Phase 3 Trial of AXS-07 in Migraine
Axsome Therapeutics, Inc. (NASDAQ: AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, today announced the acceleration of the timeline for reporting topline...
May 06, 2019 06:30 am ET
Axsome Therapeutics Announces Expedited Development and Pivotal Status for AXS-05 in the Treatment of Major Depressive Disorder based on FDA Breakthrough Therapy Meeting
Axsome Therapeutics, Inc. (NASDAQ: AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, today announced that the development status and plan for AXS-05 in the...
Apr 29, 2019 07:00 am ET
Axsome Therapeutics To Report First Quarter 2019 Financial Results On May 9, 2019
Axsome Therapeutics, Inc. (NASDAQ: AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, today announced that it will report its financial results for the first...
Apr 15, 2019 06:00 am ET
Axsome Therapeutics Announces AXS-05 Achieves Primary Endpoint in Phase 2 Trial in Smoking Cessation
Axsome Therapeutics, Inc. (NASDAQ: AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, today announced that Duke University has completed its topline analysis of...
Apr 08, 2019 08:35 am ET
Market Trends Toward New Normal in BlackBerry, Axsome Therapeutics, Pulse Biosciences, Whitestone REIT, Anworth Mortgage Asset, and Synchronoss Technologies — Emerging Consolidated Expectations, Analy
In new independent research reports released early this morning, Capital Review released its latest key findings for all current investors, traders, and shareholders of BlackBerry Limited (NYSE:BB), Axsome Therapeutics, Inc. (NASDAQ:AXSM), Pulse...
Mar 27, 2019 07:00 am ET
Axsome Therapeutics Receives FDA Breakthrough Therapy Designation for AXS-05 for the Treatment of Major Depressive Disorder
Axsome Therapeutics, Inc. (NASDAQ: AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, today announced that the U.S. Food and Drug Administration (FDA) has...
Mar 14, 2019 07:00 am ET
Axsome Therapeutics Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Business Update
Axsome Therapeutics, Inc. (NASDAQ: AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, today reported financial results for the fourth quarter and year ended...
Mar 06, 2019 07:00 am ET
Axsome Therapeutics Secures $24 Million Growth Capital Loan Facility Led by Silicon Valley Bank
Axsome Therapeutics, Inc. (NASDAQ: AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, has entered into a $24 million growth capital term loan facility with...
Mar 05, 2019 07:00 am ET
Axsome Therapeutics to Report Fourth Quarter and Full Year 2018 Financial Results on March 14, 2019
Axsome Therapeutics, Inc. (NASDAQ: AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, today announced that it will report its financial results for fiscal year...
Mar 04, 2019 07:00 am ET
Axsome Therapeutics Initiates MOMENTUM Phase 3 Trial of AXS-07 in Migraine
Axsome Therapeutics, Inc. (NASDAQ: AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, enrolled the first patient in its MOMENTUM (Maximizing Outcomes in...
Feb 06, 2019 07:00 am ET
Axsome Therapeutics Receives FDA Agreement under Special Protocol Assessment (SPA) for the MOMENTUM Phase 3 Trial of AXS-07 in Migraine
Axsome Therapeutics, Inc. (NASDAQ: AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, has reached agreement with the U.S. Food and Drug Administration (FDA)...
Jan 30, 2019 07:00 am ET
Axsome Therapeutics Initiates Phase 2 Trial of AXS-12 in Narcolepsy
Axsome Therapeutics, Inc. (NASDAQ: AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, has initiated the CONCERT (Clinical Outcomes in Narcolepsy and Cataplexy:...
Jan 08, 2019 08:31 am ET
Thinking about buying stock in Apple, Axsome Therapeutics, Luxoft, Netflix or QEP Resources?
NEW YORK, Jan. 8, 2019 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for AAPL, AXSM, LXFT, NFLX, and QEP....
Jan 07, 2019 06:35 pm ET
Axsome Therapeutics Raises $23.3 Million Under Existing ATM Facility
Axsome Therapeutics, Inc. (NASDAQ: AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, announced that today it raised approximately $23.3 million through the...
Jan 07, 2019 06:00 am ET
Axsome Therapeutics Announces AXS-05 Achieves Primary Endpoint in Phase 2 Trial in Major Depressive Disorder
Axsome Therapeutics, Inc. (NASDAQ: AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, today announced that AXS-05, a novel, oral, investigational NMDA receptor...
Dec 31, 2018 07:25 am ET
New Research: Key Drivers of Growth for Trimble, Maxar Technologies, MagnaChip Semiconductor, Palo Alto Networks, AAR, and Axsome Therapeutics — Factors of Influence, Major Initiatives and Sustained P
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Trimble Inc. (NASDAQ:TRMB), Maxar Technologies Ltd. (NYSE:MAXR), MagnaChip...
Dec 27, 2018 07:00 am ET
Axsome Therapeutics Provides Year End 2018 Clinical Update
Axsome Therapeutics, Inc. (NASDAQ: AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, today provided the following clinical update for its robust CNS pipeline:...
Dec 18, 2018 07:00 am ET
Axsome Therapeutics to Present at Biotech Showcase 2019
Axsome Therapeutics, Inc. (NASDAQ: AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, today announced that Herriot Tabuteau, MD, Axsome’s Chief Executive...
Dec 10, 2018 07:00 am ET
Axsome Therapeutics Announces Positive Outcome of Interim Analysis of ADVANCE-1 Phase 2/3 Trial of AXS-05 in Alzheimer’s Disease Agitation
Axsome Therapeutics, Inc. (NASDAQ: AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, today announced a positive outcome of the interim analysis for the...
Nov 27, 2018 07:00 am ET
Axsome Therapeutics Expands Loan Agreement with Silicon Valley Bank Providing Additional Growth Capital Related to AXS-12 Product Candidate
Axsome Therapeutics, Inc. (NASDAQ: AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, announced that its existing term loan facility agreement with Silicon...
Nov 21, 2018 08:50 am ET
Market Trends Toward New Normal in Wilhelmina International, Eyenovia, aTyr Pharma, Avinger, Viacom, and Axsome Therapeutics — Emerging Consolidated Expectations, Analyst Ratings
In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of Wilhelmina International, Inc. (NASDAQ:WHLM), Eyenovia, Inc....
Nov 19, 2018 07:00 am ET
Axsome Therapeutics to Participate in 2018 Global Mizuho Investor Conference
Axsome Therapeutics, Inc. (NASDAQ: AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, today announced that Herriot Tabuteau, MD, Axsome’s Chief Executive...
Nov 14, 2018 07:00 am ET
Axsome Therapeutics Announces Completion of Patient Enrollment in the ASCEND Phase 2 Trial of AXS-05 in Major Depressive Disorder
Axsome Therapeutics, Inc. (NASDAQ: AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, today announced the completion of patient enrollment in the ASCEND...
Nov 09, 2018 07:00 am ET
Axsome Therapeutics Reports Third Quarter 2018 Financial Results and Provides Business Update
Axsome Therapeutics, Inc. (NASDAQ: AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, today reported financial results for the third quarter ended September 30,...
Nov 01, 2018 07:00 am ET
Axsome Therapeutics to Report Third Quarter 2018 Financial Results on November 9, 2018
Axsome Therapeutics, Inc. (NASDAQ: AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, today announced that it will report its financial results for the third...
Oct 18, 2018 07:00 am ET
Axsome Therapeutics Hosts R&D Day Today with Key Opinion Leaders Focusing on AXS-05 and Unmet Needs in Alzheimer’s Disease Agitation
Axsome Therapeutics, Inc. (NASDAQ: AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, is hosting a research and development (R) day in New York City today...
Oct 17, 2018 07:00 am ET
Axsome Therapeutics Receives FDA Orphan Drug Designation for AXS-12 for the Treatment of Narcolepsy
Axsome Therapeutics, Inc. (NASDAQ: AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, received on Tuesday, October 16, Orphan Drug Designation from the U.S....
Oct 16, 2018 07:05 am ET
Axsome Therapeutics to Host Call Today with Key Opinion Leader Focusing on AXS-12 and Unmet Needs in Narcolepsy
Axsome Therapeutics, Inc. (NASDAQ:AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, is hosting a conference call and webcast with slides today at 8:00 AM...
Oct 16, 2018 07:00 am ET
Axsome Therapeutics Announces AXS-12 for the Treatment of Narcolepsy
Axsome Therapeutics, Inc. (NASDAQ: AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, today announced its next CNS product candidate, AXS-12 (reboxetine),...
Oct 12, 2018 07:00 am ET
Axsome Therapeutics to Present at Upcoming Investor Conferences
Axsome Therapeutics, Inc. (NASDAQ: AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, today announced that Herriot Tabuteau, MD, Axsome’s Chief Executive...
Oct 11, 2018 07:00 am ET
Axsome Therapeutics to Focus on Growing Core CNS Portfolio; Establishes Axsome Pain and Primary Care Business Unit to Enhance Value of Non-CNS Assets
Axsome Therapeutics, Inc. (NASDAQ: AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, today announced that it will focus on its growing core CNS portfolio. As a...
Sep 28, 2018 07:00 am ET
Axsome Therapeutics Announces $8.9 Million Registered Direct Offering
Axsome Therapeutics, Inc. (NASDAQ: AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, today announced that it has entered into a definitive purchase agreement...
Sep 24, 2018 07:00 am ET
Axsome Therapeutics to Present at Upcoming Investor Conferences
Axsome Therapeutics, Inc. (NASDAQ: AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, today announced that Herriot Tabuteau, MD, Axsome’s Chief Executive...
Sep 19, 2018 07:00 am ET
Axsome Therapeutics to Host R&D Day with Key Opinion Leaders Focused on AXS-05 and Unmet Needs in Alzheimer’s Disease Agitation
Axsome Therapeutics, Inc. (NASDAQ:AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, today announced that it will host a research and development (R) day with...
Aug 28, 2018 07:00 am ET
Axsome Therapeutics to Present at the 20th Annual Rodman & Renshaw Global Investment Conference
Axsome Therapeutics, Inc. (NASDAQ: AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, today announced that Herriot Tabuteau, MD, Axsome’s Chief Executive...
Aug 08, 2018 07:00 am ET
Axsome Therapeutics Reports Second Quarter 2018 Financial Results and Provides Business Update
Axsome Therapeutics, Inc. (NASDAQ:AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, today reported financial results for the second quarter ended June 30,...
Aug 01, 2018 07:00 am ET
Axsome Therapeutics to Report Second Quarter 2018 Financial Results on August 8, 2018
Axsome Therapeutics, Inc. (NASDAQ: AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, today announced that it will report its financial results for the second...
Jul 17, 2018 07:00 am ET
Axsome Therapeutics Announces AXS-05 Presentation at the 2018 Alzheimer’s Association International Conference
Axsome Therapeutics, Inc. (NASDAQ:AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, today announced a poster presentation on AXS-05 at the 2018 Alzheimer’s...
Jun 05, 2018 07:00 am ET
Axsome Therapeutics Initiates Phase 2 Trial of AXS-05 in Major Depressive Disorder
Axsome Therapeutics, Inc. (NASDAQ:AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, enrolled the first patient in the ASCEND (Assessing Clinical Episodes in...
May 29, 2018 07:00 am ET
Axsome Therapeutics to Present Data on AXS-05 at the 2018 American Society of Clinical Psychopharmacology Annual Meeting
Axsome Therapeutics, Inc. (NASDAQ:AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, today announced that Phase 1 pharmacokinetic and mechanism of action data...
May 22, 2018 07:00 am ET
Axsome Therapeutics to Present at the 2018 BIO International Convention
Axsome Therapeutics, Inc. (NASDAQ:AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, today announced that Herriot Tabuteau, MD, Axsome’s Chief Executive...
May 08, 2018 07:00 am ET
Axsome Therapeutics Reports First Quarter 2018 Financial Results and Provides Business Update
Axsome Therapeutics, Inc. (NASDAQ:AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, today reported financial results for the first quarter ended March 31,...
May 03, 2018 07:00 am ET
Axsome Therapeutics Announces AXS-05 Poster Presentation at the 2018 Annual Meeting of the American Psychiatric Association
Axsome Therapeutics, Inc. (NASDAQ:AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, today announced a poster presentation on AXS-05 (bupropion and...
May 01, 2018 07:00 am ET
Axsome Therapeutics to Report First Quarter 2018 Financial Results on May 8, 2018
Axsome to host conference call and webcast on Tuesday, May 8, 2018 at 8:00 AM Eastern Time
Apr 26, 2018 07:00 am ET
Apr 24, 2018 07:00 am ET
Axsome Therapeutics Hosts R&D Day Today with Key Opinion Leaders Focusing on AXS-05 and Unmet Needs in Depression, Alzheimer’s Disease Agitation, and Nicotine Dependence
NEW YORK, April 24, 2018 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ:AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, is hosting a research and development (R&D) day in New...
Apr 23, 2018 07:00 am ET
Apr 19, 2018 07:00 am ET
Axsome Therapeutics Appoints Nick Pizzie, CPA, MBA, as Chief Financial Officer
NEW YORK, April 19, 2018 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ:AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, today announced the appointment of Nick Pizzie, CPA, MBA, as...
Apr 11, 2018 07:00 am ET
Axsome Therapeutics to Participate in the Leerink Partners’ 2018 CNS Day
NEW YORK, April 11, 2018 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ:AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, today announced that Herriot Tabuteau, M.D., Axsome’s Chief Executive Officer,...
Mar 27, 2018 07:00 am ET
Axsome Therapeutics to Host R&D Day with Key Opinion Leaders Focused on AXS-05 and Unmet Needs in Depression, Alzheimer’s Disease Agitation, and Nicotine Dependence
NEW YORK, March 27, 2018 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ:AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, today announced that it will host a research and development...
Mar 26, 2018 07:00 am ET
Axsome Therapeutics to Present at H.C. Wainwright Annual Global Life Sciences Conference
NEW YORK, March 26, 2018 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ:AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, today announced that Herriot Tabuteau, M.D., Axsome’s Chief Executive Officer,...
Mar 19, 2018 07:00 am ET
Axsome Therapeutics to Present at 17th Annual Needham Healthcare Conference
NEW YORK, March 19, 2018 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ:AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, today announced that Herriot Tabuteau, M.D., Axsome’s Chief Executive Officer,...
Mar 12, 2018 07:00 am ET
Axsome Therapeutics Presents Scientific Rationale for the Development of AXS-05 at the 20th Annual Meeting of the American Society for Experimental Neurotherapeutics
NEW YORK, March 12, 2018 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ:AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, today announced presentations on AXS-05, its novel glutamatergic and monoaminergic...
Mar 07, 2018 07:00 am ET
Axsome Therapeutics Reports Fourth Quarter and Full Year 2017 Financial Results and Provides Business Update
Interim analyses of STRIDE-1 and ADVANCE-1 trials of AXS-05 anticipated in 2018
Feb 28, 2018 07:00 am ET
Axsome Therapeutics to Report Fourth Quarter and Full Year 2017 Financial Results on March 7, 2018
Axsome to host conference call and webcast on Wednesday, March 7, 2018 at 8:00 AM Eastern Time
Feb 05, 2018 07:00 am ET
Axsome Therapeutics to Present at 2018 BIO CEO & Investor Conference
NEW YORK, Feb. 05, 2018 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ:AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, today announced that Herriot Tabuteau, M.D., Axsome’s Chief Executive Officer,...
Jan 09, 2018 07:00 am ET
Dec 19, 2017 07:00 am ET
Axsome Therapeutics to Present at Biotech Showcase 2018
NEW YORK, Dec. 19, 2017 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ:AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, today announced that Herriot Tabuteau, M.D., Axsome’s Chief Executive Officer,...
Dec 14, 2017 07:00 am ET
Axsome Therapeutics Collaborates with World-Leading Nicotine Addiction Research Center for Phase 2 Trial of AXS-05 in Smoking Cessation
Builds on preclinical research conducted at Duke University and clinical research conducted by Axsome
Dec 06, 2017 07:00 am ET
Axsome Therapeutics Announces Closing of $9.5 Million Registered Direct Offering
NEW YORK, Dec. 06, 2017 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ:AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, today announced the closing of its previously announced registered direct...
Dec 01, 2017 07:00 am ET
Axsome Therapeutics Announces $9.5 Million Registered Direct Offering Priced At-the-Market
NEW YORK, Dec. 01, 2017 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ:AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, today announced that it has entered into definitive purchase agreements...
Nov 28, 2017 07:00 am ET
Axsome Therapeutics Announces AXS-07 for the Treatment of Migraine
Incorporates new molecular entity for migraine and Axsome’s MoSEIC™ technology
Nov 08, 2017 07:00 am ET
Axsome Therapeutics Reports Third Quarter 2017 Financial Results
NEW YORK, Nov. 08, 2017 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ:AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, today reported financial results for the quarter ended September 30, 2017....
Nov 08, 2017 07:00 am ET
Axsome Therapeutics Reports Third Quarter 2017 Financial Results
NEW YORK, Nov. 08, 2017 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ:AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, today reported financial results for the quarter ended September 30,...
Mar 07, 2017 04:35 pm ET
Axsome Therapeutics Reports Fourth Quarter and Full Year 2016 Financial Results and Provides Business Update
Interim analysis results from two Phase 3 trials of AXS-02 in separate indications anticipated in 2H 2017...
Nov 14, 2016 04:30 pm ET
Axsome Therapeutics Reports Third Quarter 2016 Financial Results
NEW YORK, Nov. 14, 2016 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ:AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, today reported financial results for the third quarter ended September 30, 2016....
Nov 10, 2016 07:00 am ET
Axsome Therapeutics Enters into $20 Million Term Loan Agreement with Silicon Valley Bank
NEW YORK, Nov. 10, 2016 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ:AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, announced today that it has entered into a $20 million term loan agreement with Silicon Valley Bank. Axsome intends to use the additional capital to support the ongoing development of its late-stage clinical pipeline....
Oct 04, 2016 07:00 am ET
Axsome Therapeutics Announces Publication of Research Showing AXS-02 Inhibits Pain in Animal Model of Complex Regional Pain Syndrome
NEW YORK, Oct. 04, 2016 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ:AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, today announced the publication of data showing that AXS-02 (oral zoledronate) inhibits pain in a well-validated animal model of complex regional pain syndrome (CRPS)....
Sep 19, 2016 07:00 am ET
Axsome Therapeutics to Present at the Ladenburg Thalmann 2016 Healthcare Conference
NEW YORK, Sept. 19, 2016 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ:AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, today announced that Herriot Tabuteau, M.D., Axsome’s Chief Executive Officer, will present a corporate overview at the Ladenburg Thalmann 2016 Healthcare Conference on September 27, 2016 at 8:30 AM Eastern Time. The conference will be held at the Sofitel New York in New York City....
Sep 06, 2016 07:00 am ET
Axsome Therapeutics to Present at Upcoming Investor Conferences
NEW YORK, Sept. 06, 2016 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ:AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, today announced that Herriot Tabuteau, M.D., Axsome’s Chief Executive Officer, will present a corporate overview at the following investor conferences:...
Sep 02, 2016 04:47 pm ET
Axsome Therapeutics Announces Transition of Chief Medical Officer
NEW YORK, Sept. 02, 2016 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ:AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, announced today that Randall Kaye, M.D. is transitioning from his role as Chief Medical Officer (CMO) of the Company to Senior Clinical Advisor, effective September 1, 2016. This new role allows Dr. Kaye to continue to provide his expertise to Axsome while making time for his other medical interests....
Aug 09, 2016 05:30 pm ET
Axsome Therapeutics Reports Second Quarter 2016 Financial Results
NEW YORK, Aug. 09, 2016 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ:AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, today reported financial results for the second quarter ended June 30, 2016....
Jul 05, 2016 07:00 am ET
Axsome Therapeutics to Present at the Cantor Fitzgerald 2nd Annual Healthcare Conference
NEW YORK, July 05, 2016 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ:AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, today announced that Herriot Tabuteau, M.D., Axsome’s Chief Executive Officer, will present at the Cantor Fitzgerald 2nd Annual Healthcare Conference on July 13, 2016 at 10:15 AM Eastern Time. Dr. Tabuteau will provide an overview of Axsome’s business and late-stage clinical product candidates, AXS-02 and AXS-05. The conference will be held at Le Parker Meridien in New York, N...
Jun 27, 2016 07:00 am ET
Axsome Therapeutics Added to Russell 3000® and Russell 2000® Indexes
NEW YORK, June 27, 2016 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ:AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, has been added to the broad-market Russell 3000® and small-cap Russell 2000® Indexes, as part of the Russell US Indexes annual reconstitution, effective after the US market opens on June 27....
Jun 13, 2016 07:00 am ET
Axsome Therapeutics to Present at the 2016 JMP Securities Life Sciences Conference
NEW YORK, June 13, 2016 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ:AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, today announced that Herriot Tabuteau, M.D., Axsome’s Chief Executive Officer, will present at the 2016 JMP Securities Life Sciences Conference on June 22, 2016 at 2:30 PM Eastern Time. Dr. Tabuteau will provide an overview of Axsome’s business and late-stage clinical product candidates, AXS-02 and AXS-05. The conference will be held at the St. Regis Hotel in New York, NY....
May 11, 2016 04:42 pm ET
Axsome Therapeutics Reports First Quarter 2016 Financial Results
NEW YORK, May 11, 2016 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ:AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, today reported financial results for the quarter ended March 31, 2016....